Antitumor activity of HER-2 inhibitors

被引:74
作者
Rabindran, SK [1 ]
机构
[1] Wyeth Res, Pearl River, NY 10965 USA
关键词
HER-2; ErbB-2; neu; receptor tyrosine kinase; kinase inhibitors; breast cancer;
D O I
10.1016/j.canlet.2004.11.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Activation of intracellular mitogenic signal transduction pathways driven by the ErbB family of receptor tyrosine kinases has been implicated in a variety of cancers. Amongst these, the tumorigenic roles of the Epidermal Growth Factor receptor (EGFR) and HER-2 have been most extensively studied. Therapeutic antibodies and small molecule kinase inhibitors targeting EGFR have recently received regulatory agency approval for the treatment of colon and lung cancer, respectively. In this review, I briefly describe these agents and their potential use in inhibiting the growth of tumors that overexpress HER-2. I also discuss other therapeutics currently available or being developed specifically to target HER-2 dependent tumors. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:9 / 23
页数:15
相关论文
共 156 条
[11]  
Barbacci EG, 2003, CANCER RES, V63, P4450
[12]   Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing [J].
Baselga, J .
ANNALS OF ONCOLOGY, 2002, 13 (01) :8-9
[13]  
BLACKWELL KL, 2004, J CLIN ONCOL, V22, P3006
[14]  
BOSSENMAIER B, 2004, P ANN M AM ASS CANC, V45, P5342
[15]   The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous system [J].
Britsch, S ;
Li, L ;
Kirchhoff, S ;
Theuring, F ;
Brinkmann, V ;
Birchmeier, C ;
Riethmacher, D .
GENES & DEVELOPMENT, 1998, 12 (12) :1825-1836
[16]  
BRITTEN CD, 2004, J CLIN ONCOL S14S, V22, P3045
[17]  
Bunn PA, 2001, CLIN CANCER RES, V7, P3239
[18]  
Calvo BF, 2003, CLIN CANCER RES, V9, P1087
[19]  
Camirand Anne, 2002, Med Sci Monit, V8, pBR521
[20]  
CASADO E, 2004, J CLIN ONCOL, V22, P3543